Glomerular Filtration and determinants of glomerular filtration .pptx
J.B. Vermorken - Ovarian cancer - State of the art
1. State of the Art in Ovarian cancer Jan B. Vermorken, MD, PhD Department of Medical Oncology Antwerp University Hospital Edegem, Belgium 3rd EASO Masterclass in Clinical Oncology Amman, 2011
2.
3. Five-year Survival in Ovarian Cancer 30 years of experience Vol. Year Cases Ia IV Overall (n) % 16 1963-68 4588 66.7 5.0 27.3 19 1976-78 6724 72.3 4.5 29.8 21 1982-86 10912 82.3 8.0 35.0 23 1990-92 7059 83.5 11.1 41.6 25 1996-98 4116 89.3 13.4 46.4 26* 1999-01 4911 89.3 18.6 49.7 Int. J Gynecol Obstet 2006 (Suppl 1)
28. Trial Design Ovarian cancer in complete remission after first-line platinum based chemotherapy and a normal CA125 CA125>2 x upper limit of normal RANDOMIZED Early treatment Clinician and patient informed Delayed treatment Clinician not informed , treatment delayed until clinically indicated REGISTER Blinded CA125 measured every 3 months Rustin GJ et al, Lancet 2010; vol 376: 1155-1163
29. Overall Survival HR=1.00 (95%CI 0.82-1.22) p=0.98 Early Delayed Abs diff at 2 years= 0.1% (95% CI diff= -6.8, 6.3%) Rustin GJ et al, Lancet 2010; vol 376: 1155-1163
30. Time from Randomisation to First Deterioration in Global Health Score (or death) Proportion alive without deterioration in GHS Number at risk Rustin GJ et al, Lancet 2010; vol 376: 1155-1163
41. Monk BJ et al, J Clin Oncol 2010; 28(19):3107-14.
42. An Open-label Multicenter Randomized Phase 3 Study Comparing DOXIL/CAELYX and Trabectedin with DOXIL/CAELYX Alone in Advanced ROC Monk BJ et al, submitted
43.
44. Phase 2 Randomized Placebo-controlled Study of Olaparib in Pts with Platinum-Sensitive relapsed Serous OC Ledermann J et al (# 5003) n = 265
45.
46.
47.
48.
49.
Hinweis der Redaktion
ICON7 - primary endpoint was again PFS, but in this case by RECIST criteria only, and demonstrated a statistically significant, though more modest benefit for PFS favoring the experimental arm. Similar to GOG 0218, the maximal effect appears at ~ 12 months, max duration therapy with BEV
Retrospective subset analysis of 465 with advanced disease demonstrated a more robust impact on PFS similar to GOG 218 - HR 0.68